These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26401930)

  • 1. Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease.
    Snir JA; Suchy M; Lawrence KS; Hudson RH; Pasternak SH; Bartha R
    J Alzheimers Dis; 2015; 48(1):73-87. PubMed ID: 26401930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Aspartyl Cathepsin Targeted PET Agent: Application in an Alzheimer's Disease Mouse Model.
    Snir JA; Suchy M; Bindseil GA; Kovacs M; Chronik BA; Hudson RHE; Pasternak SH; Bartha R
    J Alzheimers Dis; 2018; 61(3):1241-1252. PubMed ID: 29332035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection.
    Ta R; Suchy M; Tam JH; Li AX; Martinez-Santiesteban FS; Scholl TJ; Hudson RH; Bartha R; Pasternak SH
    Contrast Media Mol Imaging; 2013; 8(2):127-39. PubMed ID: 23281285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of cytosolic cathepsin D in Alzheimer's disease pathology: Protective cellular effects of PLGA nanoparticles against β-amyloid-toxicity.
    Wang Y; Wu Q; Anand BG; Karthivashan G; Phukan G; Yang J; Thinakaran G; Westaway D; Kar S
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):686-706. PubMed ID: 32716575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease.
    Tian L; Zhang K; Tian ZY; Wang T; Shang DS; Li B; Liu DX; Fang WG; Wang ZY; Chen YH
    J Alzheimers Dis; 2014; 42(2):511-20. PubMed ID: 24898658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
    Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
    Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease.
    Zhou W; Scott SA; Shelton SB; Crutcher KA
    Neuroscience; 2006 Dec; 143(3):689-701. PubMed ID: 16997486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of cerebral glucose uptake changes in the 5XFAD mouse.
    Macdonald IR; DeBay DR; Reid GA; O'Leary TP; Jollymore CT; Mawko G; Burrell S; Martin E; Bowen CV; Brown RE; Darvesh S
    Curr Alzheimer Res; 2014; 11(5):450-60. PubMed ID: 24801216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer's disease.
    Girard SD; Baranger K; Gauthier C; Jacquet M; Bernard A; Escoffier G; Marchetti E; Khrestchatisky M; Rivera S; Roman FS
    J Alzheimers Dis; 2013; 33(3):781-96. PubMed ID: 23042214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Dual Fluorochrome Near-Infrared Imaging Probe for Potential Alzheimer's Enzyme Biomarkers-BACE1 and Cathepsin D.
    Tam JM; Josephson L; Pilozzi AR; Huang X
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered levels and distribution of IGF-II/M6P receptor and lysosomal enzymes in mutant APP and APP + PS1 transgenic mouse brains.
    Amritraj A; Hawkes C; Phinney AL; Mount HT; Scott CD; Westaway D; Kar S
    Neurobiol Aging; 2009 Jan; 30(1):54-70. PubMed ID: 17561313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aβ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer.
    Lee M; Lee HJ; Park IS; Park JA; Kwon YJ; Ryu YH; Kim CH; Kang JH; Hyun IY; Lee KC; Choi JY
    Neuropharmacology; 2018 May; 133():512-517. PubMed ID: 29427650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Metal-Free Method for Producing MRI Contrast at Amyloid-β.
    Hilt S; Tang T; Walton JH; Budamagunta M; Maezawa I; Kálai T; Hideg K; Singh V; Wulff H; Gong Q; Jin LW; Louie A; Voss JC
    J Alzheimers Dis; 2017; 55(4):1667-1681. PubMed ID: 27911291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model.
    Reid GA; Darvesh S
    Neuroscience; 2015 Jul; 298():424-35. PubMed ID: 25931333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer's disease.
    Bobkova NV; Garbuz DG; Nesterova I; Medvinskaya N; Samokhin A; Alexandrova I; Yashin V; Karpov V; Kukharsky MS; Ninkina NN; Smirnov AA; Nudler E; Evgen'ev M
    J Alzheimers Dis; 2014; 38(2):425-35. PubMed ID: 23985416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
    Do TM; Alata W; Dodacki A; Traversy MT; Chacun H; Pradier L; Scherrmann JM; Farinotti R; Calon F; Bourasset F
    Neuropharmacology; 2014 Jun; 81():311-7. PubMed ID: 24631967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.